Cybin (HELP) has moved into focus after advancing its lead psychedelic therapy HLP003 into a Phase 3 trial for major depressive disorder, alongside leadership changes including the appointment of Michael Halstead as CEO.

Cybin’s recent progress on HLP003 and leadership hires has come alongside sharp share price swings, with a 30 day share price return of 74.21% and a 90 day share price return of 190.99%. Over a 1 year period the total shareholder return is 73.30%, but the 5 year total shareholder return remains down 86.12%, which signals strong recent momentum on top of a still heavily damaged long term record.

Scan beyond Cybin and see how other high momentum biotech and pharma stocks with solid fundamentals stack up in the 20 high quality undiscovered gems.

Cybin now has a late stage asset, fresh leadership and a stock that has surged in a short window. The key issue for investors is whether the recent share price move already reflects that progress.

Most Popular Narrative: 68.2% Undervalued

The most followed valuation narrative for Cybin places fair value at $41.62 per share compared with the last close of $13.24, which frames the recent rally as only part of the story.

Strengthened cash position, with $83.8 million at quarter end and a subsequent US$175 million financing, gives the company resources to complete key data readouts and manufacturing preparation. This can de risk execution around potential future revenue and earnings streams.

Want to see what is backing that fair value gap for Cybin? The narrative leans heavily on future revenue scale, margin lift and a rich future earnings multiple. Curious how those ingredients combine into a single target price.

Result: Fair Value of $41.62 (UNDERVALUED)

However, Cybin’s story still hinges on successful late stage trial results and careful cash use, as the company currently reports no revenue and a loss of $171.2 million.

Another View: What Cybin’s P/B Tells You

The Cybin story looks very different when you switch from fair value models to a simple P/B check. The stock trades around 4x book value, compared with 2.6x for the wider US Pharmaceuticals industry and 3.2x for peers, which points to a richer valuation on this metric.

That gap suggests investors are already paying a premium for Cybin’s late stage pipeline, despite the company remaining unprofitable and heavily reliant on future milestones. The question is whether that premium reflects conviction in the story or stretches the margin for error if sentiment cools.

Next Steps

If the mix of enthusiasm and caution around Cybin feels familiar, that is a sign to review the details yourself and act quickly on your own judgement. A useful place to start is by weighing the 2 key rewards and 6 important warning signs.

Looking for more investment ideas beyond Cybin?

If Cybin has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh stock ideas that fit your style.

• Spot opportunities that the market might be overlooking by scanning through the 20 high quality undiscovered gems.
• Prioritise resilience and sleep better at night by filtering for companies in the 76 resilient stocks with low risk scores.
• Zero in on sturdier balance sheets by reviewing the list of solid balance sheet and fundamentals (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.